Levosimendán Eql Pharma

Levosimendan, the active ingredient in Levosimendán Eql Pharma, is a calcium sensitizer presented as a solution for injection for intravenous use. It is indicated for the treatment of acute decompensated heart failure in adult patients, improving cardiac output without increasing intracellular calcium overload.

GNH USA supplies Levosimendán Eql Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to healthcare institutions across Europe, Asia, Africa and the Americas.

Levosimendan is a calcium sensitizer indicated for the treatment of acute decompensated heart failure, where it enhances myocardial contractility and induces vasodilation, thereby improving cardiac output and relieving symptoms in patients experiencing sudden worsening of heart function.

Acute decompensated heart failure (ADHF): improves myocardial contractility, reduces preload and afterload, and can facilitate weaning from mechanical ventilation in severe cases. Acute decompensated heart failure (hospitalized patients): may improve hemodynamics and reduce need for additional inotropic support when administered early. Acute decompensated heart failure with low blood pressure: provides inotropic support without increasing intracellular calcium, helping maintain perfusion.

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure, especially during rapid infusion. - Headache: mild to moderate intensity, often transient. - Nausea: occasional gastrointestinal discomfort. - Dizziness: feeling light‑headed, particularly when standing. - Tachycardia: increased heart rate in some patients. - Flushing: warm sensation and reddening of skin.

Serious or Rare Side Effects: - Severe hypotension: profound blood pressure fall requiring intervention. - Ventricular arrhythmias: potentially life‑threatening irregular heart rhythms. - Myocardial ischemia: reduced blood flow to heart muscle. - Allergic reactions: rash, itching, or anaphylaxis. - Pulmonary edema: fluid accumulation in lungs. - Renal impairment: worsening kidney function.

Levosimendan requires careful clinical monitoring and consideration of patient‑specific factors before and during therapy.

Cardiovascular monitoring: continuously observe blood pressure and heart rate during infusion. Renal impairment: use with caution in patients with severe renal dysfunction; adjust therapy as needed. Hepatic impairment: consider dose modification for those with significant liver disease. Concomitant vasodilators: avoid additive hypotensive effects when combined with other vasodilatory agents. Pregnancy and lactation: safety not established; use only if potential benefit outweighs risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, requiring vigilance to prevent adverse outcomes.

Major Interactions (Avoid): - Sodium nitroprusside: additive hypotension. - Phosphodiesterase inhibitors (e.g., milrinone): synergistic vasodilation. - Calcium channel blockers: heightened risk of low blood pressure. - Other calcium sensitizers: avoid combined use. - Strong CYP3A4 inhibitors: may increase plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and volume status. - ACE inhibitors or ARBs: watch for excessive blood pressure reduction.